Chrysin - Sacituzumab Govitecan-Hziy Interaction Details

Interaction Details

Sacituzumab Govitecan-Hziy is classified as belonging to the following category: Glucuronidated Drugs

Theoretically, chrysin might increase the clearance of drugs that are UGT1A1 substrates, thereby reducing their effectiveness.
In vitro research suggests that chrysin might induce UDP-glucuronosyltransferase 1A1 (UGT1A1).

Interaction Rating

Minor

Likelihood of Occurrence

Unlikely

Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.

References

Galijatovic A, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res 2000;17:21-6.
Walle T, Otake Y, Galijatovic A, et al. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos 2000;28:1077-82.
Galijatovic A, Otake Y, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res 2001;18:374-9.

Sacituzumab Govitecan-Hziy Overview

Sacituzumab govitecan-hziy is used to treat ertain types of breast cancer in adults that has spread to other parts of the body or cannot be removed by surgery and who have already been treated with at least two other chemotherapy medications. Sacituzumab govitecan-hziy is also used to treat certain types of urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) in adults that has spread to other parts of the body or cannot be removed by surgery and who have already been treated with at least two other chemotherapy medications. Sacituzumab govitecan-hziy is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.

See More Information Regarding Sacituzumab govitecan-hziy Injection

Chrysin - More Interactions

Chrysin interacts with 354 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.